INO Inovio Pharmaceuticals Inc

Price (delayed)

$1.13

Market cap

$92.97M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.45

Enterprise value

$75.39M

?
Relative Growth: Rel. Growth: 15
Relative Strength: Rel. Strength: 6
Relative Valuation: Rel. Valuation: N/A
Relative Profitability: Rel. Profitability: 5

INOVIO is a biotechnology company focused on rapidly bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases, cancer, and diseases associated with HPV. INOVIO ...

Highlights
INO's EPS has surged by 55% year-on-year and by 20% since the previous quarter
Inovio Pharmaceuticals's debt has decreased by 23% YoY and by 7% QoQ
INO's revenue has dropped by 100% since the previous quarter and by 100% year-on-year
The gross profit has dropped by 100% since the previous quarter and by 100% year-on-year

Key stats

What are the main financial stats of INO

INO stock price

How has the Inovio Pharmaceuticals stock price performed over time
Intraday
1.8%
1 week
1.8%
1 month
-16.3%
1 year
-41.45%
YTD
-35.06%
QTD
-35.06%

Financial performance

How have Inovio Pharmaceuticals's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$83.72M
Net income
-$84.93M
Gross margin
N/A
Net margin
N/A
INO's revenue has dropped by 100% since the previous quarter and by 100% year-on-year
The gross profit has dropped by 100% since the previous quarter and by 100% year-on-year
INO's operating income is up by 21% YoY and by 3.6% QoQ
INO's net income is up by 12% year-on-year

Price vs fundamentals

How does INO's price correlate with its fundamentals

Growth

What is Inovio Pharmaceuticals's growth rate over time

Valuation

What is Inovio Pharmaceuticals stock price valuation
P/E
N/A
P/B
12.87
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
INO's EPS has surged by 55% year-on-year and by 20% since the previous quarter
The equity has plunged by 88% YoY and by 75% from the previous quarter
INO's revenue has dropped by 100% since the previous quarter and by 100% year-on-year

Efficiency

How efficient is Inovio Pharmaceuticals business performance
INO's ROE has plunged by 89% from the previous quarter
INO's return on assets is down by 49% year-on-year and by 14% since the previous quarter

Dividends

What is INO's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for INO.

Financial health

How did Inovio Pharmaceuticals financials performed over time
The total assets is 14% greater than the total liabilities
INO's quick ratio has dropped by 61% year-on-year and by 26% since the previous quarter
INO's current ratio has shrunk by 60% YoY and by 26% QoQ
Inovio Pharmaceuticals's debt is 43% higher than its equity
The equity has plunged by 88% YoY and by 75% from the previous quarter
Inovio Pharmaceuticals's debt has decreased by 23% YoY and by 7% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.